Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
316.2 DKK | -1.43% | +1.67% | +6.82% |
Apr. 08 | Denmark's Demant Finalizes Capital Reduction | MT |
Apr. 04 | Competition Regulator Clears Cochlear’s Acquisition of Oticon Medical’s Cochlear Implant Business | MT |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- The company is in debt and has limited leeway for investment
- With a 2024 P/E ratio at 22.71 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- With an enterprise value anticipated at 3.55 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+6.82% | 9.89B | B- | ||
-8.27% | 16.43B | A | ||
+7.45% | 13.63B | B | ||
-19.87% | 2B | - | ||
+6.38% | 1.79B | B+ | ||
+37.75% | 1.64B | D- | ||
+13.95% | 600M | - | ||
0.00% | 475M | - | - | |
+26.44% | 134M | - | ||
+12.60% | 86.89M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DEMANT Stock
- Ratings Demant A/S